naion glp 1 Smaller Risk with Semaglutide Found in Large Population Non-Arteritic Anterior Ischemic Optic Neuropathy

The most important are risk of hypoglycemia, weight gain and a more complex regimen of treatment, with more injections and monitoring procedures every day

After one year off medication, the increased risk was 14%

Obesity Drug Market Size, Share & Trends Analysis Report by Drug Type/Class (GLP-1 Receptor Agonists, GIP/GLP-1 Receptor Agonists (Dual Agonists), Lipase Inhibitors, Combination Therapies, Sympathomimetic Amines, Novel Mechanisms (Emerging)), Route of Administration, Prescription Type, Treatment Duration, Indication, Age Group, Mechanism of Action, End-Users, and Geography (North America, Europe, Asia Pacific, Middle East, Africa, and South America) Global Industry Data, Trends, and Forecasts, 20262035 Obesity Drug Market Size, Share, and Growth The global obesity drug market is witnessing strong growth, valued at USD 7.3 billion in 2025 and projected to reach USD 50.3 billion by 2035, expanding at a CAGR of 21.3% during the forecast period

Although we have long known that A1C targets are not effective, this guideline recommends focusing completely on cardiovascular and renal risk as long as A1C is less than 9%

Benefits and Risks of GLP-1 Agonists Benefits: Significant Weight Loss: Studies show substantial weight loss (15-20% in some cases) when combined with lifestyle changes

Several SeekPeptides community members report that setting hourly water reminders on their phones made a bigger difference in their GLP-1 experience than any single supplement change